
|Articles|June 1, 2003
Moxifloxacin gains FDA approval
Author(s)Lynda Charters
Dallas-Moxifloxacin ophthalmic solution (Vigamox 0.5%, Alcon Laboratories) was approved by the FDA on April 16 for the treatment of bacterial conjunctivitis, following a 6-month review of the drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
PRIMA retinal implant restores vision in patients with advanced GA
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
5














































